

SEC Number : CS201506626
File Number : _____

**ALLIED CARE EXPERTS (ACE) DUMAGUETE
DOCTORS INC.**

(Company's Full Name)

DML Building, Northroad, Dumaguete City
(Company's Address)

008-997-532-000
(TIN Number)

(035) 421-2119
(Telephone Number)

-
(Fax Number)

SEC FORM 20-IS
DEFINITIVE INFORMATION STATEMENT

Form Type

Each Active Secondary License Type and File Name: NONE

**SECURITIES AND EXCHANGE COMMISSION
SEC FORM 20-1S
INFORMATION STATEMENT PURSUANT TO SECTION 20
OF THE SECURITIES REGULATION CODE**

1. Check the appropriate box:

- Preliminary Information Statement
 Definitive Information Statement

2. Name of Registrant as specified in its charter: **ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS INC.**

3. Province, country or other jurisdiction of incorporation or organization: **Negros Oriental, Philippines**

4. SEC Identification Number: **CS201506626**

5. BIR Tax Identification Code: **008-997-532-000**

6. Address of Principal Office: Postal Code:

DML Building, Northroad, Dumaguete City 6200

7. Registrant's telephone number, including area code: (035) 421 2119

8. Date, time and place of the meeting of security holders:

Date : **July 2, 2026**
Time : **8:00 a. m.**
Place : **F. Cimafranca St., Daro, Dumaguete City
Via Zoom Webinar**

9. Approximate date on which the Information Statement is first to be sent or given to security holders:
June 10, 2026

10. In case of Proxy Solicitations: NOT APPLICABLE

Name of Person Filing the Solicitation Statement:
Address and Tel. No. :

11. Securities registered pursuant to Section 8 and 12 of the Code or Section 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding/ Amount of Debt Outstanding
Common Shares	As at March 31, 2026 – P168,820,000.00
Amount of Outstanding Debt	As at March 31, 2026 – P50,000,000.00

12. Are any or all registrant's securities listed in a Stock Exchange?

Yes No

PART I

INFORMATION REQUIRED IN INFORMATION STATEMENT

A. GENERAL INFORMATION

Date, time and place of meeting of security holders.

(a) The stockholders' meeting shall be held on:

Date : **July 2, 2026**
Time : **8:00 a. m.**
Place : **F. Cimafranca St., Daro, Dumaguete City**
Via Zoom Webinar

Complete Mailing Address of Principal Office of Registrant:

ALLIED CARE EXPERTS (ACE) DUMAGUETE DOCTORS INC.

DML Building, Northroad, Dumaguete City

The approximate date on which the information statement is first to be sent and given to security holders shall be **June 10, 2026**.

Dissenter's Right of Appraisal

There is a proposed amendment to Article II of the articles of incorporation included in the Agenda of the meeting which may give rise to a possible exercise by security holders of their appraisal right. The proposed amendment, approved by the Board of Directors on March 12, 2026, covers the inclusion of the following allied activity among the Company's secondary purposes: the provision of accredited Continuing Professional Development Trainings by the Corporation to licensed nurses.

Under Section 80, Title X of the Revised Corporation Code of the Philippines, the stockholders of the Corporation have the right of appraisal under the following instances:

- a. In case an amendment to the articles of incorporation has the effect of changing or restricting the rights of any stockholder or class of shares, or of authorizing preferences in any respect superior to those outstanding shares of any class, or of extending or shortening the term of corporate existence;
- b. In case of sale, lease, exchange, transfer, mortgage, pledge or other disposition of all or substantially all of the corporate property and assets as provided in this Code;
- c. In case of merger or consolidation; and
- d. In case of investment of corporate funds for any purpose other than the primary purpose of the corporation.

Further, under Section 81 of the Revised Corporation Code, the dissenting stockholder who votes against a proposed corporate action may exercise the right of appraisal by making a written demand on the corporation for the payment of the fair value of shares held within thirty (30) days from the date on which the vote was taken. Provided that failure to make the demand within such period shall be deemed a waiver of the appraisal right. If the proposed corporate action is implemented, the corporation shall pay the stockholder, upon surrender of the certificate of stock representing the stockholders' shares, the fair value thereof as of the day before the vote was taken, excluding any appreciation or depreciation in anticipation of such corporate action.

If, within sixty (60) days from the approval of the corporate action by the stockholders, the withdrawing stockholder and the corporation cannot agree on the fair value of the shares, it shall be determined and appraised by three (3) disinterested persons one of whom shall be named by the stockholder, another by the corporation, and the third by the two (2) appraisers thus chosen. The findings of the majority of the appraisers

shall be final and their award shall be paid the corporation within thirty (30) days after such award is made; Provided, That no payment shall be made to any dissenting stockholder unless the corporation has unrestricted retained earnings in its books to covers such payment; Provide, further, That upon payment by the corporation of the agreed or awarded price, the stockholder shall forthwith transfer the shares to the corporation.

Interest of Certain Persons in or Opposition to Matters to be Acted Upon

No director, officer or nominee for election as director of the Company, or associate of a director, officer, or nominee for election as director has any substantial interest in any matter to be acted upon, other than election to office. No director has informed the Company in writing that he intends to oppose any action to be taken by the Company at the meeting.

B. CONTROL AND COMPENSATION INFORMATION**Voting Securities and Principal Holders Thereof**

(a) Class of Voting Shares as of March 31, 2026:

	Shares Outstanding	No. of Vote Each Share Is Entitled
Common Shares:		
Filipino	168,560	One (1) vote per share
Foreign	260	One (1) vote per share
Total	168,820	

(b) Record Date:

All stockholders of record as of June 11, 2026, are entitled to notice of and to vote at the Annual Stockholders' Meeting.

(c) Manner of voting:

The holders of common stock are entitled to one vote per share, except in connection with the election of directors where only the founders are entitled to vote. The founders are entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. A founder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast via the online tool in the Zoom Webinar. In all matters included in the agenda, except the election of directors, the counting of votes will be done through the regular method.

(d) Security Ownership of Certain Record and Beneficial Owners and Management

(1) Security Ownership of Certain Record and Beneficial Owners (of more than 5%) as of March 31, 2026

The persons known to the registrant to be directly or indirectly the record or beneficial owner of more than 5% of the registrant's voting securities as of March 31, 2026, are as follows:

Title of Class	Name, Address of record owner and Relationship with Issuer	Name of Beneficial Owner and Relationship with Record Owner	Citizenship	No. of Shares Held	Percent
Common Founder	Enriquez, Amado Manuel C. Jr.	Enriquez, Amado Manuel C. Jr.	Filipino	12,500	7.48%

(2) Security Ownership of Directors and Management as of March 31, 2026:

Name	Amount and Nature of Beneficial Ownership		Citizenship	No. of Shares	% Ownership
	Direct	Indirect			
BOARD OF DIRECTORS					
Amado Manuel C. Enriquez Jr.	12,500,000	7,500,000	Filipino	19,920 (common shares) 80 (founder shares)	11.85%
Geanie A. Cerna-Lopez	4,340,000	3,160,000	Filipino	7,470 (common shares) 30 (founder shares)	4.44%
Robert H. Tan	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%
Marietta T. Samoy	7,500,000	-	Filipino	7,470 (common shares) 30 (founder shares)	4.44%
Roy Diamond M. Arco	3,330,000	10,000	Filipino	3,330 (common shares) 10 (founder shares)	1.98%
Brenda V. Diputado	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Ronald I. Ramiro	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%
Esmeralda V. De La Rosa	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%
Michael Edward R. Enriquez	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Revey S. Nuico	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%
Franciene P. Vasquez	2,490,000	10,000	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Idelle Marie A. Yurong	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Concepcion P. Rosario	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Eulenia P. Nolasco	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%
Generoso M. Orillaza	2,500,000	2,500,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%

Name	Amount and Nature of Beneficial Ownership		Citizenship	No. of Shares	% Ownership
	Direct	Indirect			
EXECUTIVE OFFICERS					
Amado Manuel C. Enriquez Jr. / Chairman	12,500,000	7,500,000	Filipino	19,920 (common shares) 80 (founder shares)	11.85%
Geanie A. Cerna-Lopez / Vice Chairperson	4,340,000	3,160,000	Filipino	7,470 (common shares) 30 (founder shares)	4.44%
Robert H. Tan / President	2,490,000	2,510,000	Filipino	4,980 (common shares) 20 (founder shares)	2.96%
Marietta T. Samoy / Vice President	7,500,000	-	Filipino	7,470 (common shares) 30 (founder shares)	4.44%
Brenda V. Diputado / Corporate Secretary	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Roy Diamond M. Arco / Corporate Treasurer	3,330,000	10,000	Filipino	3,330 (common shares) 10 (founder shares)	1.98%
Aejeleth B. Eyas / Asst. Corporate Secretary	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%
Michael Edward R. Enriquez / Asst. Corporate Treasurer	2,500,000	-	Filipino	2,490 (common shares) 10 (founder shares)	1.48%

(3) There are no voting trust holders of 5% or more.

(4) The Company is not aware of any voting trust agreement/s or similar agreement/s which may result in a change in control of the Company.

(e) No change in control of the registrant has occurred since the beginning of its last fiscal year.

Directors and Executive Officers

(a) Directors/Nominees and Executive Officers

There are fifteen (15) members of the Board, three (3) of whom are independent directors. The term of office of each member is one (1) year; they are elected at the annual stockholders' meeting to hold office until the next succeeding annual stockholders' meeting and until his/her successor is elected and qualified. A director who is elected to fill any vacancy holds office only for the unexpired term of his predecessor. The current members of the Board of Directors are the following:

1. Amado Manuel C. Enriquez Jr.
2. Marietta Samoy
3. Geanie Cerna-Lopez
4. Robert H. Tan
5. Michael Edward Enriquez
6. Ronald Ramiro

7. Esmeralda De La Rosa
8. Roy Diamond M. Arco
9. Revey Nuico
10. Franciene Vasquez
11. Brenda Diputado
12. Idelle Marie Yurong
13. Concepcion Rosario - Independent Director
14. Eulenia Nolasco – Independent Director
15. Generoso Orillaza – Independent Director

The nominees for this year are the following:

1. Amado Manuel C. Enriquez Jr.
2. Marietta Samoy
3. Geanie Cerna-Lopez
4. Robert H. Tan
5. Michael Edward Enriquez
6. Roberto De Leon
7. Junabeth Credo
8. Jonathan Amante Jr.
9. Karen Sayson
10. Angelo Michael Singco
11. Raponzel Fontelo
12. Silahis Rosario
13. Angelo Alcalá - Independent Director
14. Nestor Jogie Arroryo – Independent Director
15. Felix Nolasco – Independent Director

Please refer to attached Annex “A” for the summary of qualifications of the current Directors, Officers and Nominees.

The Company has complied with the guidelines on the nomination and election of independent directors as set forth in Rule 38 of the Amended Implementing Rules and Regulations of the Securities Regulation Code. The nominated independent directors are as follows: Concepcion Rosario, Eulenia Nolasco, and Generoso Orillaza, were nominated by Silahis Rosario, Aejeleth Eyas and Robert H. Tan, respectively. The nominees are not related to their respective nominating stockholder and were pre-screened by the Nominations Committee, composed of Robert H. Tan (Chairman), Generoso Orillaza (Independent Director), Geanie Cerna-Lopez, Glenda Nuico, Corazon Uy, Marilou Buenaventura (non-voting) and Miguel Antonio Enriquez (non-voting).

The Company’s key executive officers as of March 31, 2026, are as follows:

Name	Position
Amado Manuel C. Enriquez Jr.	Chairman
Geanie Cerna-Lopez	Vice Chairman
Robert H. Tan	President
Marietta Samoy	Vice President
Roy Diamond M. Arco	Corporate Treasurer
Brenda V. Diputado	Corporate Secretary
Aejeleth B. Eyas	Assistant Corporate Secretary
Michael Edward R. Enriquez	Assistant Corporate Treasurer

The Officers (per the Company’s By-Laws) are elected/appointed annually by the Board of Directors during its organizational meeting following the annual stockholders’ meeting, each to hold office for one

(1) year until the next organizational meeting of the Board in the following year or until a successor shall have been elected/appointed and shall have qualified. Please refer to attached Annex "A" for the summary of qualifications of the Executive Officers.

Significant Employees

The Corporation relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Corporation's goals. All the employees are expected to have significant contribution, based on their respective positions, to the business of the Corporation.

Certain Relationships and Related Transactions

The Company, in the normal course of business, transacts business with individuals which are considered related parties. The following were carried out with related parties as at March 31, 2026 and December 31, 2025:

Category	Advances from shareholders 2025	Amount of Transactions 2026	Advances from shareholders 2026	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	47,558,354	2,454,165	50,012,519	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	47,558,354	2,454,165	50,012,519		

Category	Advances from shareholders 2024	Amount of Transactions 2025	Advances from shareholders 2025	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	27,945,354	19,613,000	47,558,354	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	27,945,354	19,613,000	47,558,354		

(a) Non-interest-bearing Advances from shareholders

In the special meeting of the Board held last May 7, 2017, the directors and shareholders were mandated and empowered to contribute resources and make cash advances to the Company for the development of its medical structures and appurtenances. In view of this, the shareholders advanced the monies in support of the Company's building construction requirements. These advances are non-interest bearing and to be paid subject to availability of funds and/or the Board may decide to convert said advances to equity in the distant future. The Company, however, also reserves the right to defer settlement and prioritize completion of the hospital building.

(b) Interest-bearing Advances from shareholders

On June 3, 2019, the Company acquired an unsecured interest-bearing advance from the shareholders at 12% per annum which was primarily used by the Company to support the working capital requirement during the start of its operation. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

Family Relationships

Among the directors and officers of Allied Care Experts (ACE) Dumaguete Doctors, Inc., the assistant corporate treasurer, Michael Edward Enriquez, is the son of Dr. Amado Manuel Enriquez, Jr. a member of the Board of Directors. There are no other directors or officers, aside from the aforementioned, who have family relationship.

Involvement in Certain Legal Proceedings

As of April 30, 2026, the following Directors are parties to legal proceedings in their capacity as Directors of the Company:

1. Geanie A. Cerna-Lopez
2. Amado Manuel C. Enriquez, Jr.
3. Ronald L. Ramiro
4. Marietta T. Samoy
5. Generoso M. Orillaza

Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City (Complaint for Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney’s Fees) - Dax Matthew M. Quijano, Rosemarie P. Quijano, Eric Y. Cheung, Girlie Cheung, Candice Joy A. Sia vs. ACE Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez Jr., Floram C. Limotlimot, Roland Mark M. Gigataras, Joy C. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado

On March 7, 2018, complainants Dax Matthew M. Quijano, Rosemarie P. Quijano, Eric Y. Cheung, Girlie Cheung, Candice Joy A. Sia, through counsel filed a civil complaint against the Hospital and its Directors (as stated above) praying the Court to direct the defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff’s Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase in capital approved by the Board on November 12, 2016.

The Defendants have already filed their Answer to the Complaint.

We filed a Motion to Dismiss the Complaint for lack of interest of the plaintiffs to prosecute the case last August 5, 2020. A Judicial Dispute Resolution was scheduled but failed. Case is up for pre-trial conference.

The judicial dispute resolution (JDR) failed. The case is up for pre-trial conference on April 13, 2023

The 13 April 2023 pre-trial of the case was cancelled and moved to 02 June 2023 at 10:45am. The 02 June 2023 pre-trial was cancelled and moved to 11 August 2023 at 10:45am. The 11 August 2023 pre-trial was cancelled and moved to 20 October 2023 at 10:00 in the morning.

During the 20 October 2023, the plaintiffs' counsel asked the Court to render a partial judgment recognizing the sale in installment as a subscription contract. We objected and requested that their request for partial judgment be put into writing so that we can make an informed comment on the matter. Plaintiffs were given 15 days to file and the same number of days was granted to us to comment on their filing. The next pre-trial is scheduled on 22 December 2023 at 10:00 in the morning. The 22 December 2023 hearing was reset to 15 March 2024 at 10:30 am.

On October 17, 2024, Baduel Espina & Associates confirmed their appearance during the October 16, 2024 hearing. The court needed more time to resolve the plaintiff's Motion for Partial Summary Judgment, and the pre-trial conference was rescheduled to February 05, 2025.

On May 23, 2025, during the pre-trial hearing, the Court informed the parties and counsels that the draft resolution on the motion for partial summary judgment had not yet been finalized. Consequently, the pre-trial conference was rescheduled to July 25, 2025, at 10:00 a.m.

Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City (Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney's Fees) – Ferdinand P. Kionisala vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez, Jr., Floram C. Limotlimot, Roland Mark M. Gigataras, Joy C. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald S. Ramiro, Marietta T. Samoy, and Evangeline Y. Zozobrado

On February 5, 2018, complainant Ferdinand P. Kionisala filed a civil complaint against the Hospital and its Directors (as stated above) praying the Court to direct the defendants ACE Medical Center Cebu and its President and Corporate Secretary to issue the plaintiff's Certificate of Stock and declare the sale in installment as subscription contract, to allow him to exercise pre-emptive rights to the increase in capital approved by the Board on November 12, 2016.

The Defendants (based in Cebu) have already filed their Answer to the Complaint and Dr. Kionisala has filed a Motion for Partial Summary Judgment, but the same was opposed by the defendants on May 15, 2018. The Court has not yet ruled on the plaintiff's Motion for Partial Summary Judgment of May 2, 2018. Unless the Court resolves the Motion for Summary Judgment by the plaintiff, the case will not move on.

The Defendants filed a Motion to Dismiss the case for failure of the plaintiff to prosecute for lack of interest. The case was scheduled for Pre-Trial on April 30, 2021. Pre-trial was terminated. Case is set for presentation of plaintiff's evidence.

The Court rendered on August 9, 2022 a partial summary judgement on plaintiff's prayer for issuance of certificate of stock leaving the other issues sought for trial on the merits. However, instead of presenting his evidence plaintiff filed a motion to submit the case for decision based on legal issues through the filing of memorandum which is still pending for resolution.

Plaintiff has submitted his motion to submit case for decision based on legal issues, which was submitted to the Court on October 24, 2022. We filed our comment on November 7, 2022. We received an order dated 30 June 2023 where the Court has granted the motion to submit case for decision based on legal issues dated 18 October 2022. The Presiding Judge has granted both parties to file their respective memorandum, which shall be limited to the

issue of the extent of plaintiff's preemptive right to purchase/subscribe to shares of stock in view of the defendant Corporation's increase in its capital stock, within 30 days from receipt of said order.

Our Counsel filed a Motion for Reconsideration to set aside and deny Plaintiff's motion to submit case for decision based on the sole issue of whether the plaintiff is entitled to the preemptive right to subscribe to one block of share equivalent to 10 shares or only for 3 shares for utter lack of merit. The Plaintiff's Counsel opposed the Motion for Reconsideration filed by our Counsel. Awaiting decision of the Court on both Motion's.

Special Civil Action Case No. R-CEB-18-08795-SC, Branch XI, Cebu City (For Mandamus to Issue 100% Pre-Emptive Rights, Damages and for Attorney's Fees) - Leo T. Sumatra, Sps. Stephen Paul M. Bergado and Conchita B. Bergado, Marie Davielene Beatriz Ong-Dy and Leonard Matthew Dy, et. Al vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez and Velma T. Chan

The Petitioners have filed a Special Civil Action case for Mandamus, to compel the Respondents to immediately issue their 100% pre-emptive rights. The Petitioners claim they are entitled to 10 shares based on their computation of 0.000083333 ownership multiplied by 120,000 (increase in Capital).

Respondents received the Court Order on 11 December 2018. On November 25, 2020 at 8:30AM, a Judicial Dispute Resolution was conducted by RTC Branch 12, Cebu City via video conference hearing. Both parties did not come into an agreement. The Petitioners demanded PHP 600,000.00 from the Respondents. The case was scheduled for Pre-Trial on June 11, 2021. Pre-trial was terminated. Case is set for presentation of petitioners' evidence.

Presentation of petitioners' evidence. Petitioners have so far presented two (2) witnesses.

Petitioners have submitted their motion to submit case for decision based on legal issues, which was submitted on November 7, 2022. Case has been submitted for resolution. Last February 3, 2023, the scheduled hearing pushed through, and Counsel appeared for and on behalf of ACEMCCEBU, despite the pending motion.

On February 15, 2023, the Court denied the request of the Petitioners' motion to submit the case for decision based on the remaining sole legal issue. As stated in the Order, the presentation of evidence for the petitioners will push through as scheduled on 03 March 2023 at 10:45 in the morning. The hearing was cancelled upon receipt of a Constancia dated 27 February 2023 and reset to 28 April 2023 at 10:45 in the morning.

During the 28 April 2023 hearing, the Court still needs to resolve the pending Motion for Reconsideration filed by the Petitioners. Without prejudice to the resolution of the pending incident, the next hearing is set at on 30 June 2023 at 10:45am for presentation of Petitioners' evidence. Considering petitioners' motion for reconsideration has yet to be resolved, the 30 June 2023 hearing was reset to 28 July 2023 at 10:45 am. Due to the pending motion for reconsideration, the 28 July 2023 hearing was reset to 25 August 2023 at 10:45am. The 25 August 2023 was rescheduled to 29 September 2023 at 10:45am. The 29 September 2023 hearing was reset to 14 December 2023 at 10:45am. The 14 December 2023 hearing was reset to 15 March 2024 at 8:30am.

On September 26, 2024, Court hearing where the cross-examination of Mr. Peter Sylianco was continued. The petitioners were granted five days to file their Reply to the opposing party's Motion for Production, Inspection, and Photocopying of Documents, with the opportunity for the opposing side to file a rejoinder within the same period. Reimbursement

requests for transcript costs were also submitted. The next scheduled, October 24, 2024, hearing for the continuation of petitioners' evidence presentation, with unspecified subsequent procedural activities. November 28, 2024, attendance confirmed for a hearing focusing on the continuation of the presentation of evidence. Petitioners intended to present Atty. Jarred Cabilte. December 12, 2024, the parties confirmed their appearance to continue cross-examination of Leo Sumatra and other petitioners' evidence. Additional scheduled dates include March 28, April 25, and May 23, 2025, among others, for various stages of evidence presentation and testimony.

As of April 30, 2026, none of the nominees for election as director, executive officer, underwriter or control person of the registrant has been involved in the following: (1) Bankruptcy; (2) Conviction by final judgment; (3) Being subject to any Order, Judgment or Decree; and (4) Violation of Securities or Commodities Law.

No director has resigned or declined to stand for re-election to the board of directors since the date of the last annual meeting of security holders due to disagreement with the registrant on any matter relating to the registrant's operations, policies, and practices.

There is no action to be taken with respect to: (a) merger or consolidation of the registrant into or with any other person or of any other person into or with the registrant; (b) acquisition by the registrant or any of its security holders of securities of another person; (c) acquisition by the registrant of any other going business or of the assets thereof; (d) sale or transfer of all or any substantial part of the assets of the registrant; and € liquidation or dissolution of the registrant.

There is no acquisition or disposition of property.

There is no restatement of Assets, Capital or Surplus Accounts

(b) Compensation of Directors and Executive Officers

SUMMARY COMPENSATION TABLE

(a)	(b)	(c)	(d)	(e)
Name & Principal Position	Year	Salary	Bonus	Other Compensation
A. Amado Manuel C. Enriquez, Jr. Chairman	2025	1,270,000	- 0 -	- 0 -
B. Robert H. Tan President	2025	1,270,000	- 0 -	- 0 -
C. Roy Diamond M. Arco Corporate Treasurer	2025	815,000	- 0 -	- 0 -
D. Brenda V. Diputado Corporate Secretary	2025	665,000	- 0 -	- 0 -
E. Aggregate For The Above Named CEO & Officers	2026-estimate	2,280,000	- 0 -	- 0 -
	2025	4,020,000	- 0 -	- 0 -
	2024	2,287,000	- 0 -	- 0 -
F. Aggregate For The Officers And Directors As A Group	2026-estimate	6,150,000	- 0 -	- 0 -
	2025	6,982,500	- 0 -	- 0 -
	2024	4,177,000	- 0 -	- 0 -

- a. The directors receive per diem of P10,000.00/board meeting and P5,000.00 per committee meeting during board/committee meetings for each director. On November 30, 2020, the Board approved the compensation for officers, as follows:

Position	Amount
Chairman	90,000
President	90,000
Vice Chairman	80,000
Vice President	80,000
Corporate Treasurer	65,000
Assistant Treasurer	60,000
Corporate Secretary	65,000
Assistant Corporate Secretary	60,000

For the year 2025, the directors received per diem for attendance in board and committee meetings as shown in the table below:

Name of Director	Total Per Diem Received for the Year 2025
Amado Manuel C. Enriquez, Jr.	288,000
Marietta T. Samoy	288,000
Geanie A. Cerna-Lopez	288,000
Robert H. Tan	288,000
Roy Diamond M. Arco	220,500
Esmeralda Dela Rosa	54,000
Brenda V. Diputado	99,000
Revey S. Nuico	72,000
Idelle Marie A. Yurong	72,000
Ronald Ramiro	180,000
Franciene P. Vasquez	40,500
Michael Edward R. Enriquez	234,000
Eulena Nolasco	72,000
Concepcion P. Rosario	58,500
Generoso Orillaza	162,000

- b. There are no bonuses, profit sharing or other compensation plan, contract or arrangement in which any director, nominee for election as director, or executive officers of the registrant will participate.
- c. The Company has no existing options, warrants or rights to purchase any securities.
- d. The value of the securities is based on the approved issue price thereof as stated in the Registration Statement of the Corporation.

(c) Independent Public Accountants

The Company's external auditor is the auditing firm of Perez Sese Villa & Co CPAs; the same auditor is being recommended by the Board, for year 2026, based on the recommendation of the Audit Committee composed of Engr. Generoso Orillaza (Independent Director), Roy Diamond Arco, Michael Edward Enriquez, Esmeralda De La Rosa and Revey Nuico, subject to stockholders' approval.

The Audit Committee has the function of assessing the independence and professional qualifications of the external auditor, in compliance with the requirements under applicable law, rules and regulations; reviewing the performance of the external auditors. Prior to the commencement of the audit, the Audit Committee shall discuss, review and recommend with the external auditors the nature, scope and fees of the audit.

Representatives of Perez Sese Villa & Co. CPAs are expected to be present during the annual stockholders' meeting. The representatives will have the opportunity to make statements if they desire to do so and will be available to respond to appropriate questions from the security holders.

During the two (2) most recent fiscal years or any subsequent interim period, the independent auditor has not resigned nor was dismissed nor has declined to stand for reappointment after the completion of the current audit; there were no disagreements with the said independent accountants on any matter of accounting and financial disclosure.

The aggregate annual external audit fees billed for each of the last two (2) fiscal years for the audit of the registrant's annual financial statements or services that are normally provided by the external auditor are as follows:

For the year 2025- ₱156,800 .00 (billed and paid in 2025)
For the year 2024- ₱201,600.00 (billed and paid in 2025)

-

The above audit fees include audit, other assurance and related services by the External Auditor that are reasonably related to the performance of the audit or review of the Company's financial statements (a) P140,000.00 in 2025, and P180,000 in 2024; and (b) All Other P16,800.00 in 2025, and P21,600 in 2024).

Except for the audit of the Company's financial statements, no other professional services are rendered to the Company by the external auditor.

C. OTHER MATTERS

Action with Respect to Reports

The approval of the stockholders on the following will be taken up:

- i. Minutes of the July 3, 2025 Annual Stockholders' Meeting. The Minutes cover the following items:
 - I. Call to Order
 - II. Invocation
 - III. Determination of Quorum
 - IV. Welcome Message from the Chairman of the Board
 - V. Reading and Approval of the Minutes of the Y2024 Annual Stockholders' Meeting
 - VI. Approval of the Y2024 Audited Financial Statement
 - VII. President's Report
 - VIII. Ratification of the Acts and Proceedings of the Board of Directors, Officers, and Management of the Corporation
 - IX. Election of the Board of Directors 2025-2026
 - X. Appointment of External Auditor for the year 2025
 - XI. Other Matters
 - XII. Adjournment

The approval or disapproval of the above Minutes will refer only to the correctness of the Minutes and will not constitute an approval/disapproval of the matters stated in the Minutes.

- ii. Audited Financial Statements for the year ending 31 December 2025.

Other Proposed Actions

1. Ratification of all corporate acts and resolutions during the past year of the Board, Officers and Management. These acts are covered by resolutions duly adopted in the usual course of business such as opening of bank accounts and designation of authorized signatories for various transactions, etc.
2. Amendment of Article II of the articles of incorporation
3. Amendment of Section 1, Article II of the Bylaws
4. Election of Directors for Y2026-2027
5. Appointment of External Auditor for fiscal year ending 31 December 2026

Amendment of Charter, By-Laws and other Documents

On March 12, 2026, the Board approved the following amendments of the articles of incorporation and Bylaws of the Corporation:

Section 1, Article II of the Bylaws

-changing its annual stockholders' meeting date from "every 1st Sunday of May" to "every 1st Thursday of July".

-The change in the ASM date shall provide the Company enough time to prepare the reports and materials to be presented in the ASM.

Article II of the Articles of Incorporation

-to include in its secondary purpose, the provision of accredited Continuing Professional Development Trainings by the Corporation to licensed nurses.

- The additional activity shall support the Company's nurses in complying with their professional requirements while also establishing a new revenue stream for the Company.

The said proposed amendment shall be presented to the stockholders for approval in this year's annual stockholders' meeting.

Voting Procedures

Except on the election of directors, an affirmative vote by the stockholders owning at least a majority of the outstanding capital stock shall be sufficient to approve matters requiring stockholder's action. The holder of a majority interest of all outstanding stock of the Company entitled to vote at the meeting, in person or by proxy, shall constitute a quorum for the transaction of business. The holders of common stocks are entitled to one vote per share, except in connection with the election of directors where only the founders are entitled to vote. The founders shall be entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. The founder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast via the online poll thru the Zoom Webinar. Stockholders shall be entitled to vote either in person or by proxy.

Method of Counting Votes

The Corporate Secretary, assisted by the Company's external auditor, will be responsible for counting the votes.

Compliance with Section 49 of the Revised Corporation Code

Voting was done through the online poll that was launched during the annual stockholders meeting. The tabulation of the votes was done by the Board of Canvassers based on the votes received thru the online poll.

The stockholders were given the opportunity to ask their questions through the chatroom during the meeting. There were no questions raised by the stockholders.

The following matters were taken up:

- I. Call to Order
- II. Invocation
- III. Determination of Quorum
- IV. Welcome Message from the Chairman of the Board
- V. Reading and Approval of the Minutes of the Y2024 Annual Stockholders' Meeting
- VI. Approval of the Y2024 Audited Financial Statement
- VII. President's Report
- VIII. Ratification of the Acts and Proceedings of the Board of Directors, Officers, and Management of the Corporation
- IX. Election of the Board of Directors 2025-2026
- X. Appointment of External Auditor for the year 2025
- XI. Other Matters
- XII. Adjournment

Except for the election of officers, all the matters taken up were approved by the stockholders present during the meeting.

Attached as Annex "D" is the list of the directors, officers and stockholders who attended the meeting. Also attached as Annex "E", is the Attendance Sheet of the Directors for the year 2025. Attached as Annex "F" is a copy of the Minutes of the Y2025 annual stockholders meeting.

Except on the election of directors, an affirmative vote by the stockholders owning at least a majority of the outstanding capital stock shall be sufficient to approve matters requiring the stockholder's action. The holder of a majority interest of all outstanding stock of the Company entitled to vote at the meeting, in person or by proxy, shall constitute a quorum for the transaction of business. The holders of common stocks are entitled to one vote per share, but in connection with the cumulative voting feature applicable to the election of directors, each stockholder is entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. A stockholder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast thru the online platform to be launched during the meeting. Stockholders shall be entitled to vote either in person or by proxy.

Below is the Board Performance Appraisal Report for the year 2025:

PERFORMANCE ASSESSMENT FOR THE BOARD OF DIRECTORS

(January 1, 2025- December 31, 2025)

Good Corporate Governance Principles and Practices	Rating
1. The Board is composed of competent, hardworking members that foster the long-term success of the corporation and sustain its competitiveness and growth.	5
2. The Board is headed by a competent and qualified chairperson.	5
3. The Board practices diversity which avoids groupthink and ensures that optimal decision-making is achieved.	4
4. The Board members act on a fully-informed basis, in good faith, with due diligence and care, and in the best interest of the company and the shareholders and all other stakeholders	5
5. The Board oversees the development of and approves the company's business and strategy and monitor its implementation, in order to sustain the company's long-term viability and strength	5
6. The Board ensures an effective succession planning program for directors, key officers and Management to ensure the continuous and consistent growth of the company.	5
7. The Board aligns the remuneration of key officers and board members with the long-term interest of the company.	5
8. The Board has adopted a formal nomination and election policy which provides for the procedures on how the Board accepts nominations.	5
9. The Board ensures the integrity of related party transactions and other unusual transactions, particularly those which pass certain threshold materiality. The Board reviews and approves material RPTs to guarantee fairness and transparency of the transactions.	5
10. The Board has an internal control system in place and a mechanism to monitor and manage potential/actual conflicts of interests of board members, management and shareholders.	5

11. Board has organized board committees to support the effective performance of the board functions, particularly, with respect to audit, risk management, compliance and other key corporate governance concerns, such as nomination and remuneration.	5
12. The Board endeavors to exercise an objective and independent judgment on all corporate affairs.	5
13. The Board has at least 2 independent directors, or at least 20% of the members of the Board, whichever is higher.	5
14. The Board regularly carries out evaluations to assess its performance as a body, and whether it possesses the right mix of backgrounds and competencies.	4
15. The Board applies high ethical standards, taking into account the interests of all stakeholders.	5
16. The Board has established corporate disclosure policies and procedures that are practical and in accordance with generally accepted best practices and regulatory expectations.	5

On June 3, 2019, the Company acquired an unsecured interest-bearing advances from the shareholders and/or Board of Directors at 12% per annum which was primarily used by the Company to support the working capital requirement during the start of its operation. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction.

Except for per diem (P10,000.00/board meeting and P5,000.00 per committee meeting) for each director, there are no bonuses, profit sharing, or other compensation plans, contract, or arrangement in which any director, nominee for election as a director, or executive officer of the registrant will participate. For the year 2025, the following executive officers receive compensation as such officers:

(a)	(b)	(c)	(d)	(e)
Name & Principal Position	Year	Salary	Bonus	Other Compensation
A. Amado Manuel C. Enriquez, Jr. Chairman	2025	1,270,000	- 0 -	- 0 -
B. Robert H. Tan President	2025	1,270,000	- 0 -	- 0 -
C. Roy Diamond M. Arco Corporate Treasurer	2025	815,000	- 0 -	- 0 -
D. Brenda V. Diputado Corporate Secretary	2025	665,000	- 0 -	- 0 -
E. Aggregate For The Above Named CEO & Officers	2026- estimate	2,280,000	- 0 -	- 0 -
	2025	4,020,000	- 0 -	- 0 -
	2024	2,287,000	- 0 -	- 0 -
F. Aggregate For The Officers And Directors As A Group	2026- estimate	6,150,000	- 0 -	- 0 -
	2025	6,982,500	- 0 -	- 0 -
	2024	4,177,000	- 0 -	- 0 -

For the year 2025, the directors received per diem for attendance in board and committee meetings as shown in the table below:

Name of Director	Total Per Diem Received for the Year 2025
Amado Manuel C. Enriquez, Jr.	288,000
Marietta T. Samoy	288,000
Geanie A. Cerna-Lopez	288,000
Robert H. Tan	288,000
Roy Diamond M. Arco	220,500
Esmeralda Dela Rosa	54,000
Brenda V. Diputado	99,000
Revey S. Nuico	72,000
Idelle Marie A. Yurong	72,000
Ronald Ramiro	180,000
Franciene P. Vasquez	40,500
Michael Edward R. Enriquez	234,000
Eulena Nolasco	72,000
Concepcion P. Rosario	58,500
Generoso Orillaza	162,000

The directors receive per diem of P10,000.00/board meeting and P5,000.00 per committee meeting during board/committee meetings for each director. On November 30, 2020, the Board approved the compensation for officers, as follows:

Position	Amount
Chairman	90,000
President	90,000
Vice Chairman	80,000
Vice President	80,000
Corporate Treasurer	65,000
Assistant Treasurer	60,000
Corporate Secretary	65,000
Assistant Corporate Secretary	60,000

The Company has put in place, sufficient internal controls and risk management system to ensure the efficient management of the various risks concomitant to our hospital operations.

The Company's external auditor is the auditing firm of Perez Sese Villa and Co. CPAs.

The aggregate annual external audit fees billed for year 2025 was ₱156,800.00. The said fees include: (a) audit, other assurance and related services by the External Auditor that are reasonably related to the performance of the audit or review of financial statements (₱140,000.00); and (b) All Other Fees, including estimated out of pocket expenses accrued by the Company as of December 31, 2025 (Php₱16,800.00).

The Company has not yet declared dividends since its incorporation in 2015, considering that it does not have earnings yet. As stated in the Company's By-Laws, dividends shall be declared and paid out of the unrestricted retained earnings which shall be payable in cash, property, or stock to all stockholders on the basis of outstanding stock held by the stockholders as often and at such times as may be decided by the Board of Directors.

The directors have no self-dealing or related party transactions as of December 31, 2025.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this report is true, complete and correct. This report is signed in the City of Dumaguete on **May __, 2026**.

ALLIED CARE EXPERTS(ACE) DUMAGUETE DOCTORS INC.

By:

BRENDA V. DIPUTADO

Corporate Secretary

Upon the written request of the stockholder, the Company undertakes to furnish said stockholder a copy of SEC Form 17-A free of charge, except for exhibits attached thereto which shall be charged at cost. Any written request for a copy of SEC Form 17-A shall be addressed as follows:

Allied Care Experts(ACE) Dumaguete Doctors Inc.

F . Cimafranca St. Daro, Dumaguete City 6200

Attention: The Corporate Secretary

ANNEX “A”

INCUMBENT BOARD OF DIRECTORS/OFFICERS/NOMINEES

Hereunder is the complete and updated list of the directors, officers and nominees of the Corporation:

Name	Business and Professional Work Experience
Incumbent Board of Directors	
<p>Enriquez, Amado Manuel Jr. C. 73, Filipino</p>	<p>Chairman – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015-2023, 2024-present) Director – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Alaminos Medical Center Foundation (2001-present) Founding Director - Mania</p> <p>Active consultant in Cardiovascular-Thoracic Surgery – St. Luke’s Medical Center, Manila East Medical Center, ACE Medical Center Hospitals.</p> <p>Previous Positions Held: Chairman of the Board – Manila East Medical Center (2007-2008, 2017); Paranaque Doctors Hospital (2012-2017); ACE Medical Center Baypointe, Subic (2007-2011); Unihealth Paranaque Hospital (2014-2017)</p> <p>Founding Chairman – ACE Medical Center Valenzuela, ACE Medical Center Baliwag, ACE Medical Center Pateros, ACE Medical Center Malolos, ACE Medical Center Mandaluyong, ACE Medical Center Palawan, ACE Medical Center Iloilo, ACE Medical Center Tacloban, ACE Dumaguete Doctors, Inc., ACE Dumaguete Doctors, Inc., ACE Medical Center Bacolod, ACE Medical Center General Santos, ACE Medical Center CDO, ACE Medical Center Dipolog, ACE Medical Center Zamboanga, ACE Medical Center Butuan</p>
<p>Samoy, Marietta T. 69, Filipino</p>	<p>Corporate Secretary – Allied Care Experts (ACE) Dumaguete Doctors Inc., (2021-2023) Vice President - Allied Care Experts (ACE) Dumaguete Doctors Inc., (2023-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Obstetrics and Gynecology Consultant in Las Pinas, Muntinlupa and Paranaque.</p> <p>Medical Center Muntinlupa Medical Services Head, Las Pinas City Medical Center- Administrator, Uni-Health Paranaque</p>

Name	Business and Professional Work Experience
	<p>Hospital and Medical center- management consultant. Paranaque Doctors Hospital, Head Ob-Gyne Dept.</p> <p>Past President Las Pinas Med Center (2014) , Past president UniHealth Paranaque (2016) , Treasurer- medical center Muntinlupa (2015) , Past Corp Sec Paranaque Doctors Hospital (2013), Medical Director - Paranaque Doctors Hospital (2010-2012).</p> <p>Founder – Las Pinas Medical Center, Paranaque Doctors Hospital, Medical Center Muntinlupa, Metrosouth Medical Center, Unihealth Paranaque Hospital and Medical Center, Diliman Doctors Hospital</p> <p>-</p>
Cerna-Lopez, Geanie 71, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>President - Las Pinas City Medical Center, Medical Director- Unihealth Paranaque, Management Consultant - Medical Center Muntinlupa,</p> <p>Past President - Medical Center Muntinlupa (2016), Past Hospital Admin - UniHealth Paranaque Hospital (2016) and Las Pinas City Medical Center(2016); Past president Paranaque Doctors Hospital (2015)</p> <p>Trainings Attended: Center for Global Best Practices</p> <ul style="list-style-type: none"> - Corporate Governance Best Practices of Effective Boards
Tan, Robert H. 66, Filipino	<p>President – Allied Care Experts (ACE) Dumaguete Doctors Inc., (2023-present)</p> <p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant, General Surgeon, Holy Child Hospital (1993-present);</p> <p>Consultant, General Surgeon, ACE Dumaguete Doctors</p> <p>Visiting Consultant, General Surgery Silliman University Medical Centre (1993 - present)</p> <p>Trainings Attended: Center for Global Best Practices</p> <ul style="list-style-type: none"> - Corporate Governance Best Practices of Effective Boards

Name	Business and Professional Work Experience
<p>Arco, Roy Diamond M. 49, Filipino</p>	<p>Treasurer - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015-2020, 2021-2023,2024-present) Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015) Consultant, ACE Dumaguete Doctors and Silliman Medical Center Department Chairperson – ACEDDI Hemodialysis Unit Corporate Treasurer - ACEDDI PGI – SUMCFI Residency Training – Perpetual Succuor Hospital Cebu City, Internal Medicine Fellowship Training – National Kidney & Transplant Institute, Adult Nephrology Diplomate – Philippine College of Physicians (2009) Diplomate – Philippine Society of Nephrology (2012) Member of Professional Organization: Negros Oriental Medical Society, PCP Negros Oriental & Philippine Society of Nephrology</p> <p>Trainings Attended: Center for Global Best Practices - Corporate Governance Best Practices of Effective Boards</p>
<p>De la Rosa, Esmeralda 70, Filipino</p>	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>College of Medicine – University of Santo Tomas 1980 PGI – Manila Doctors Hospital 1981 Residency – Internal Medicine, East Avenue Medical Center 1983-1987</p>
<p>Diputado, Brenda 70, Filipino</p>	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc. College of Medicine - West Visayas State College PGI - UP-PGH 1981 Residency - UP-PGH – Pediatrics 1983-1985 ; Neurology 1989-1992</p> <p>Trainings Attended: Center for Global Best Practices - Corporate Governance Best Practices of Effective Boards</p>

Name	Business and Professional Work Experience
Nuico, Revey 70, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc. College of Medicine – MHAM College of Medicine PGI – Siliman University Medical Center, 1983 Residency – General Surgery, Cebu City Medical Center, 1988</p>
Yurong, Idelle Marie 58, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant of ACE Dumaguete Doctors Inc. College of Medicine – Cebu Doctor's College of Medicine PGI – Siliman University Medical Center 1993 Residency – Pediatrics, Chong Hua Hospital 2000</p>
Ramiro, Ronald 69, Filipino	<p>Founder – Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Assistant Corporate Secretary - Allied Care Experts (ACE) Dumaguete Doctors Inc. (present)</p> <p>President – ACEMC-Bohol (present)</p> <p>Graduated from CIM in 1981 and finished residency in General surgery as Chief Resident at Cebu Doctors Hospital in 1989 Passed only part 1 of the Philippine Board of Surgery in 1993</p>
Vasquez, Franciene 51, Filipino	<p>Founder - Allied Care Experts (ACE) Dumaguete Doctors Inc. (2015)</p> <p>Consultant, ACE Dumaguete Doctors and Silliman Medical Center PGI - SUMCFI Residency Training – Philippine General Hospital, OB-GYN Ultrasound and Velez General Hospital, OB-GYN Fellowship – Philippine Obstetric & Gyne Society Diplomate – Philippine Board of Obstetric & Gyne Society</p>
Enriquez, Michael Edward 38, Filipino	<p>College of Medicine – University of Santo Tomas 2017 Affiliated with ACE Group of Hospitals Outstanding inter in Emergency Medicine by the Philippine General Hospital 2018</p>
Nolasco, Eulenia/Independent Director 74, Filipino	<p>Consultant, Asian Hospital and Medical Center, Manila Doctors Medical Center President, Philippine Society of Gastroenterology President, Philippine Society of Digestive Endoscopy Head, Gastrointestinal Center, UP-PGH Medical Center Head, Gastrointestinal Section, East Ave. Medical Center Chairman, Dept. of Medicine, UPHRMC, Las Pinas City Food and Drug Administration Consultant and Drug Reviewer</p>

Name	Business and Professional Work Experience
	Member of Editorial Board, World Journal of Gastroenterology
Rosario, Concepcion/Independent Director 61, Filipino	Siliman University – BS Medical Technology Gullas College of Medicine – Doctor of Medicine PGI – Siliman University Medical Center Philippine General Hospital – Residency in Obstetrics and Gynecology Philippine Board of Obstetrics and Gynecology – Diplomate Philippine Board of Obstetrics and Gynecology – Fellow
Orillaza, Generoso/Independent Director 69, Filipino	Director – Paranaque Doctors Hospital (2007 – present); ACE Baypointe Hospital & Medical Center (2010- present); ACE Baliwag (2012-2014) Head, Engineering and Maintenance Service- ACE Valenzuela (2011-2014); ACE Baypointe Hospital & Medical Center (2010-present); ACE Baliwag (2012-2014); Unihealth Paranaque Hospital and Medical Center 2014-2014); ACE Pateros (2013-2015); ACE QC (2013-present); Chairman of Construction Committee (2008 – present) – ACE Iloilo; ACE Gensan; ACE Cebu; ACE Tacloban; ACE Butuan
Nominees for Election as Members of the Board of Directors	
Enriquez, Amado Manuel C. Jr.	<i>Please see foregoing director's profile</i>
Samoy, Marietta T.	<i>Please see foregoing director's profile</i>
Cerna, Geanie L.	<i>Please see foregoing director's profile</i>
Tan, Robert H.	<i>Please see foregoing director's profile</i>
Enriquez, Michael Edward	<i>Please see foregoing director's profile</i>
De Leon, Roberto M. 70, Filipino	Chairman, Unihealth-Baypointe Hospital & Medical Center, Inc. (Subic Bay Freeport Zone) 2017 President, Unihealth-Valenzuela Hospital & Medical Center 2017 Medical Director, YGEIA Medical Center Chairman, Dept. of Surgery, ACE Medical Center Valenzuela; Uni-Health Paranaque Hospital and Medical Center 2017
Credo, Junabeth C. 56, Filipino	Consultant, ACE Dumaguete Doctors ACE Dumaguete Doctors - Director, Warehouse ACE Dumaguete Doctors - Director, Endoscopy Section ACE Dumaguete Doctors - Chief of Clinics PGI – SUMCFI Residency Training – Silliman University Medical Center Fellowship Training – University of the Philippines – Philippine General Hospital, Manila Philippine Medical Association – Lifetime Member Philippine Society of Gastroenterology – Diplomate Philippine Society of Digestive Endoscopy - Diplomate
Amante, Jonathan K. Jr. 37, Filipino	Consultant, ACE Dumaguete Doctors ACE Dumaguete Doctors - Director, Radiology and Imaging

Name	Business and Professional Work Experience
	PGI – SUMCFI Residency Training – Cardinal Santos Medical Center
Sayson, Karen Mae A. 57, Filipino	Consultant, ACE Dumaguete Doctors College of Medicine – Cebu Institute of Medicine PGI – SUMCFI Residency Training – Holy Child Hospital Fellowship Training – Perpetual Succour Hospital – Cebu Hear Institute Diplomate – Internal Medicine Diplomate – Adult Cardiology Philippine Medical Association – Lifetime Member
Singco, Angelo Michael 61, Filipino	Consultant, ACE Dumaguete Doctors Director, ACEDDI Engineering Facilities / OR Complex PGI – SUMCFI Residency Training – Vicente Sotto Memorial Medical Center Cebu City, Surgery Philippine Medical Association – Lifetime Member Negros Oriental Medical Society – Member Pain Society of the Philippines – Member International College of Surgeon, Phil Sector – Fellow Phil. Academy of Medical Specialists, Inc. – Diplomate
Fontelo, Raponzel Josephine A. 53, Filipino	Consultant of ACE Dumaguete Doctors Inc. College of Medicine – MHAM College of Medicine PGI – Sacred Hear Hospital, 1998-1999 Residency – Holy Child Hospital, Dumaguete City, 2001-2003
Rosario, Silahis 64, Filipino	Consultant, ACE Dumaguete Doctors Chairperson, ACEDDI Department of Internal Medicine PGI – Davao Doctor's Hospital Residency Training – Siliman University Medical Center Dumaguete City, Dept. of Internal Medicine Fellowship Training – St. Luke's Medical Center Heart Institute, Adult Cardiology / Echocardiography Diplomate – Philippine College of Physician, Internal Medicine Diplomate – Philippine College of Cardiology, Adult Cardiology Negros Oriental Medical Society – Member Philippine Heart Association - Member Philippine Lipid Society - Member Cardiac Rehabilitation Society of the Philippines - Member
Alcala, Angelo 71, Filipino	Medical Director, Las Pinas City Medical Center Deputy Administrator/Consultant, Metro Iloilo Hospital and Medical Center Director, ACE Baliwag Hospital and Medical Center Chairman, Department of Medicine, Unihealth Paranaque Hospital and Medical Center

Name	Business and Professional Work Experience
	<p>Founding member and Consultant, UHBI- Paraque Doctors Hospital Consultant, Internal Medicine, Las Pinas Doctors Hospital; Perpetual Help Medical Center Las Pinas; New Sinai MDI Hospital; Medical Center Muntinlupa</p>
<p>Arroyo, Nestor Jojie 60, Filipino</p>	<p>Diplomate, Philippine Board of Anesthesiology Member, Philippine Medical Association Las Pinas Medical Society Consultant, Anesthesiologist: Muntinlupa – Paranaque – Las Pinas Holdings Inc. South Seed – LDPH College, Southville International School Alabang Medical Center Asian Eye Institute</p>
<p>Nolasco, Felix 73, Filipino</p>	<p>Chairman Emeritus, Department of Otolaryngology-HNS, East Avenue Medical Center President, Philippine Board of Otolaryngology – Head and Neck Surgery Inc 2020 President, Philippine Society of Otolaryngology-Head and Neck Surgery, Inc, 2005 Founding President, Philippine Academy of Craniomaxillofacial Surgery -PSO-HNS Inc. Former President, Allied Care Experts Med Center – Baypointe Former Vice Chairman and Vice President, Member of the Board of Directors, Administrator, Medical Director, CFO of various hospitals</p>

MANAGEMENT REPORT

A. Independent Auditor

During the two most recent fiscal years or any subsequent interim period, the Company’s independent accountant, Perez Sese Villa and Co. CPAs has not resigned, nor was dismissed or otherwise ceased performing services for the Company; there were no disagreements with the said independent accountant on any matter of accounting and financial disclosure.

B. Description of Business

Allied Care Experts (ACE) Dumaguete Doctors Inc. (the “Company”) was incorporated as a domestic corporation under Philippine laws and was duly registered with the Securities and Exchange Commission (SEC) under SEC Registration No. CS201506626 on April 1, 2015.

The Company’s primary purpose is to establish, maintain, operate, own and manage hospitals, medical and related healthcare facilities and businesses such as but without restriction to clinical laboratories, diagnostic centers, ambulatory clinic, condo-hospital, scientific research institutions and other allied undertakings and services which shall provide medical, surgical, nursing, therapeutic, paramedic or similar care, provided that purely professional medical or surgical services shall be performed by duly qualified and licensed physicians or surgeons who may or may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

The principal office of the Company is located at DML Building, North Road, Dumaguete City. The hospital construction site is located at Cimafranca St., Daro, Dumaguete City, Negros Oriental.

On February 19, 2019, the Company’s registration was approved under BOI Certificate of Registration No. 2019-034. Thus, the Company is now eligible to enjoy certain grants, particularly, but not limited to – Income Tax Holiday—for a period of 4 years starting from November 2018 or actual start of commercial operations, whichever is earlier (the availment of which shall not be earlier than the date of registration).

The Company was likewise able to secure its license to operate from the Department of Health as a Level II Hospital on June 25, 2019.

Competition

The Company’s principal competitors are the following:

HOSPITAL	LOCATION	BED CAPACITY	CATEGORY	LEVEL CLASSIFICATION
Holy Child Hospital	Bishop Epifanio Surban Street, Dumaguete City	200	Private	Level I
Silliman Medical Center Foundation Inc.	Hibbard Ave, Dumaguete City	300	Private	Level III
Negros Oriental Provincial Hospital	National Highway, Dumaguete City	200	Public	Level I
Negros Polymedic Hospital	Tubtubon, National Highway, Sibulan	100	Private	Level II

The patients will opt to be serviced by ACE Dumaguete Doctors considering its accessibility especially in emergency cases. The Company's good location, quality of the facilities and its competent medical staff will be the hospital's edge over its competitors.

Suppliers

The Company has no existing supply contracts with the principal suppliers. The Company has a broad base of suppliers. The Company is not dependent on one or a limited number of suppliers.

Customers

The Company is not dependent upon a single customer or a few customers due to the nature of the industry.

Government Regulations

Required permits were secured by the Company from the Department of Health (DOH), Food and Drug Administration (FDA) and Philippine Drug Enforcement Agency (PDEA) as part of the normal course of the hospital operations.

The Company has secured the required permits and clearances from the Department of Environment and Natural Resources (DENR) to be able to operate its hospital facility. Implementation of the environmental laws cost ACE-Dumaguete Doctors around P100,000 annually.

The Company is not involved in any legal proceedings.

Employees

Total number of full-time employees as of March 31, 2026, is 527. The breakdown is as follows:

	CBA	Non-CBA	Total
Rank and File	370	114	484
Supervisors	–	31	31
Managers and Top Management	–	12	12
Total	370	157	527

Apart from their regular compensation, the employees are entitled to hospital management discounts as follows:

Services	Regular Employee Discounts
Pharmacy	10%
OR Set	10% (OR Materials)
Laboratory	25%
EEG/ECG/2D Echo/Treadmill	25%
Professional fees	25%
Radiology	25% (Contrast not included)
Physical Therapy	25% (For 10 sessions)
ER Fee	50%
OR Fee	50%
DR Fee	50%
Room Accommodation	50% (45 days only)

Discounts for hospital staff employees and rank and file employees should not exceed ₱75,000 per year while discounts for head nurses, supervisors and department chiefs should not exceed ₱175,000 per year.

The Company does not expect to hire additional employees in the next 12 months.

C. Securities of the Registrant

Market Price, Dividend and Related Stockholder Matters

The securities of Allied Care Experts (ACE) Dumaguete Doctors Inc. are not listed in any stock exchange. Its securities are marketed through its organic salaried employees who serve as salesmen. The high and low sales prices by quarter for the last two (2) years are as follows:

	1st Quarter		2nd Quarter		3rd Quarter		4th Quarter		1st Quarter
Market Price	2024	2025	2024	2025	2024	2025	2024	2025	2026
High	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000
Low	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000	250,000

The price as of March 31, 2026 (latest practicable trading date) is P250,000.

There are no debt securities, stock options, securities subject to redemption or call, or warrants to be registered or issued.

There are no securities to be modified or exchanged.

There are no recent sales of unregistered or exempt securities including recent issuance of securities constituting an exempt transaction.

There are approximately 1,842 holders of common and founders shares of the Company as of March 31, 2026. Trading of Company's shares is sporadic.

Please refer to Annex "C" for the list of top 20 stockholders as of March 31, 2026.

No dividends were declared in 2025, 2024 and 2023 considering that the Company has no unrestricted retained earnings yet available for dividend declaration.

There are no restrictions that limit the payment of dividends on Common Shares. The Company's Loan Agreement with the Landbank does not provide for any restriction on the dividend declaration by the Company.

D. Management's Discussion and Analysis or Plan of Operation

For the First Quarter of 2026

Financial Performance (1st Q 2026)

For the three months ended March 31, 2026, the Company's operation has generated net revenue of P181.4 million.

UNAUDITED INTERIM STATEMENTS OF FINANCIAL PERFORMANCE

	For the three months ended March 31			
	2026	2025	Peso change	% Change 2026 v 2025
Revenue, net	₱151,134,232	₱181,410,211	(₱30,275,979)	-17%
Direct costs	(108,189,768)	(123,621,871)	(15,432,103)	-12%
Gross profit	42,944,464	57,788,340	(14,843,876)	-26%
General and administrative expenses	(36,479,836)	(43,930,019)	(7,450,183)	-17%
Net operating income (loss)	6,464,628	13,858,321	(7,393,693)	-53%
Finance cost	(1,359,463)	(4,367,097)	(3,007,634)	-69%
Net income (loss) before other charges	5,105,165	9,491,224	(4,386,059)	-46%

Other charges and income, net	1,845,825	770,924	1,074,901	139%
Net income (loss)	₱6,950,990	₱10,262,148	(₱3,311,158)	-32%

Revenue in 2026 has significantly decreased by 17% or ₱30.3 million due to decrease in occupancy rate and out-patient census. Direct costs decrease to ₱108.2 million in 2026 from ₱123.6 million in 2025 or a 12% decrease due to the decrease in cost of medicines, depreciation and cost of laboratory reagents used. Direct costs includes depreciation; cost of medicines, medical supplies and laboratory reagents; professional fee of resident and junior consultants; salaries and wages of medical staff; and allocated utilities expense.

The Company's operating expenses pertain mainly to salaries and other benefits of administrative employees, allocated depreciation expense, utilities expense, repairs and maintenance, supplies and consumables, and security services which represent 78% of the Company's total operating expenses. The total operating expenses has decreased by 17% or ₱7.5 million in 2026 as compared to 2025. This is due to the decrease in the depreciation, and repairs and maintenance cost of the medical equipment of the Company.

Other charges and income includes other income, interest income and income tax expense for the period.

Financial Position (1st Q 2026)

UNAUDITED INTERIM STATEMENTS OF FINANCIAL POSITION

	March 31, 2026 (Unaudited)	December 31, 2025 (Audited)	Peso change	% Change 2026 v 2025
Current assets	₱219,857,875	₱258,713,776	(₱38,855,901)	-15%
Noncurrent assets	650,614,522	654,411,135	(3,796,613)	-1%
Total assets	870,472,397	913,124,911	(42,652,514)	-5%
Current liabilities	216,695,611	268,753,280	(52,057,669)	-19%
Noncurrent liabilities	55,759,756	53,305,591	2,454,165	5%
Total liabilities	272,455,367	322,058,871	(49,603,504)	-15%
Total equity	598,017,030	591,066,040	6,950,990	1%
Total liabilities and equity	870,472,397	913,124,911	(42,652,514)	-5%
Current assets/Total assets	25%	28%		
Current ratio	101%	96%		
Debt to equity ratio	46%	54%		

Balance Sheet Items – 1st Q 2026 compared to 2025

The net decrease in current assets mainly pertains to the decrease in cash amounting to ₱53.6 million which was partially offset by the increase in trade receivables amounting to ₱11.6 million.

The noncurrent assets of the Company mainly consist of property and equipment and advances for capital acquisition. The net decrease is mainly due to the depreciation expense which was partially offset by the acquisition of new medical equipment of the Company acquired for the three months ended March 31, 2025.

The liabilities of the Company mainly consist of payables to suppliers, statutory payables and advances from shareholders. The decrease was mainly due to payment of payables to suppliers and payment of principal of the long-term loan from Landbank of the Philippines.

Material Variances Affecting the Statements of Financial Position

Statement of financial position accounts as of March 31, 2026 with variances of plus or minus 5 percent against December 31, 2025 balance are discussed, as follows:

Current assets

1. Cash - The increase in cash is due to payments of accounts payable and loans payable during the 1st quarter of the year. The Company has a decrease of ₱53.6 million. This was offset by availment of additional short-term loan amounting to ₱25.0 million.
2. Trade and other receivables – The increase in accounts receivable of 14% is due to the increase in receivable from patients and receivable from government agencies which is typical for the 1st quarter of the year. In 2026, trade receivables has increased from ₱83.1 million to ₱94.7 million.
3. Inventories – The increase in inventories is due to the increase of goods or services available to patients. Inventories has increased by 14% or ₱11.6 million in 2026.
4. Prepayments and other current assets – The increase is due to receipt of creditable withholding tax and input VAT.

Noncurrent assets

1. Advances to suppliers – The increase on the account can be attributed to the advance payments for the acquisition of multiple medical equipment which is expected to be delivered in 2026.
2. Intangible assets – The decrease in intangible asset is due to the amortization recognized.

Current and Noncurrent Liabilities

1. Trade and other payables – The decrease in the account is due to the payments of payables to suppliers and medical practitioners.
2. Loans payable - In 2026, the Company has paid a total of ₱24.0 million to its long-term loans payable and ₱10.0 million to its short-term loans payable which was partially off-set by the availment of additional short-term loan amounting to ₱25.0 million.
3. Advances from shareholders – The increase is due to receipts made throughout the year.

For the Full Fiscal Years

Financial Performance (2025)

The following table shows the financial highlights of the Company for the years then ended December 31, 2025 and 2024:

	2025	% to Sales	2024	% to Sales	% Change 2025 v 2024
Total Revenue, net	₱609,670,225	100%	₱613,058,922	100%	-1%
Total Cost of Sales	413,673,473	68%	417,694,316	68%	-1%
Gross Income	195,996,752	32%	195,364,606	32%	0%
Total Gen & Ad Expense	160,504,123	26%	153,663,061	25%	4%
Operating income (loss)	35,492,629	6%	41,701,545	7%	-15%
Other charges (income)	(13,280,744)	-2%	(13,850,719)	-2%	-4%
Net Income (Loss)	₱22,211,885	4%	₱27,850,826	5%	-20%

The company operates a state-of-the-art facility with a 110-bed capacity, equipped with advanced digital information systems and staffed by highly trained medical professionals, including specialist doctors. This exceptional infrastructure has enabled the company to maintain consistent profitability over the past three years. The outpatient services offered encompass a wide range of medical procedures, including laboratory testing, radiology and imaging, cardio-pulmonary diagnostics, nuclear medicine, and outpatient consultations.

Revenue in 2025 has decreased by 1% or ₱3.4 million due to increase in inpatient occupancy rate and OPD census. Cost of sales has decreased to ₱413.7 million in 2025 from ₱417.7 million in 2024 or a 1% decrease. Cost of sales includes depreciation; cost of medicines, medical supplies and laboratory reagents; professional fees, salaries and wages and utilities expense.

The Company's operating expenses pertain mainly to salaries and wages of administrative employees, repairs and maintenance, allocated depreciation and amortization expense, supplies and consumable, and bad debt expense which represent 67% of the Company's total operating expenses. The total operating expenses increased by 4% or ₱6.8 million in 2025.

In 2025, the Company has generated net income of ₱22.2 million.

Financial Position (2025)

The following table shows the financial position of the Company as at December 31, 2025 and 2024:

	December 31, 2025	% to Total Assets	December 31, 2024	% to Total Assets	% Change
Current assets	₱258,713,776	28%	₱178,383,714	21%	45%
Noncurrent assets	654,411,135	72%	684,559,217	79%	-4%
Total assets	913,124,911	100%	862,942,931	100%	6%
Current liabilities	268,753,280	29%	246,390,899	29%	9%
Noncurrent liabilities	53,305,591	6%	53,197,877	6%	0%
Total Liabilities	322,058,871	35%	299,588,776	35%	8%
Total Equity	591,066,040	65%	563,354,155	65%	5%
Total liabilities and equity	913,124,911	100%	862,942,931	100%	6%

Balance Sheet Items - 2025 compared to 2024

Total current assets increased by 45% or ₱80.3 million in 2025 as compared to 2024. The decrease in current assets is due to increase in cash amounting to ₱90.8 million. The Company has total assets of ₱913.1 million as of December 31, 2025 of which ₱605.7 million or 66% is comprised of the Company's land, building, medical equipment and other properties and equipment.

The liabilities of the Company is mainly consist of accounts payable to suppliers, medical practitioners and related parties, and loans payable to the Land bank of the Philippines totaling ₱59.0 million as of December 31, 2025. Total current liabilities have increased by 131% or ₱119.1 million in 2025 as compared in 2024 due to increased payable to suppliers and medical practitioners.

Material Variances Affecting the Statements of Financial Position

Statement of financial position accounts as of December 31, 2025 with variances of plus or minus 5 percent against December 31, 2024 balance are discussed, as follows:

Current assets

5. Cash - The increase in cash is due to increase in cash generated from operating activities particularly better collection rate from government and government agencies. The Company has an increase of ₱90.8 million. This was offset by the loan payments. Total payments amounted to ₱120.8 million in 2025 and ₱122.0 million in 2024.
6. Trade and other receivables – The decrease in accounts receivable of 18% is due to the decrease in receivable from patients, PHIC, HMO, Corporate and GLs. In 2025, receivable from HMO, Corporate and GLs decreased from ₱97.3 million to ₱83.1 million. This is due to the increased in collection rate from financial assistance from government agencies.
7. Inventories – The increase in inventories is due to the increase of goods or services available to patients. Inventories has increased by 21% or ₱6.7 million in 2025.

- Prepayments and other current assets – The decrease is due to utilization of creditable withholding tax.

Noncurrent assets

- Advances to suppliers – The increase on the account can be attributed to the advance payments for the acquisition of multiple medical equipment which is expected to be delivered in 2026.
- Property and equipment – The decrease is mainly due to the depreciation of the Company’s property and equipment totaling to ₱69.8 million which is slightly offset by acquisition of new machineries and equipment totaling to ₱39.3 million.
- Deferred tax assets – Increase in deferred tax asset is due to the additional recognition of provision for ECL and retirement obligation. The account has increased by 40% or ₱1.5 million

Current and Noncurrent Liabilities

- Trade and other payables – The increase in the account is due to the increase in payables to suppliers and medical practitioners.
- Loans payable - In 2025, the Company has paid a total of ₱120.8 million to its long-term notes payable which caused the decrease in total current and noncurrent notes payable.
- Advances from shareholders – The increase is due to receipts made throughout the year.

Financial Performance (2024)

The following table shows the financial highlights of the Company for the years then ended December 31, 2024 and 2023:

	2024	% to Sales	2023	% to Sales	% Change 2024 v 2023
Total Revenue, net	₱613,058,922	100%	₱605,497,294	100%	1%
Total Cost of Sales	(417,694,316)	68%	(446,741,620)	74%	-7%
Gross Income	195,364,606	32%	158,755,674	26%	23%
Total Gen & Ad Expense	(153,663,061)	25%	(112,759,792)	19%	36%
Operating income	41,701,545	7%	45,995,882	8%	-9%
Other charges	(13,850,719)	-2%	(24,131,611)	-4%	-43%
Net Income	₱27,850,826	5%	₱21,864,271	4%	27%

The Company started its hospital out-patient department operations last March 2019. Out-patient operations include laboratory and radiology procedures, ECG, EEG, 2D Echo, Bone Densitometry and Doctor’s clinic consultations. On July 2019, the Company started operating in-patient services. The Company has a 100-bed capacity.

Revenue in 2024 has increased by 1% or ₱7.6 million due to increase in inpatient occupancy rate and OPD census. Cost of sales has decreased to ₱417.69 million in 2024 from ₱446.7 million in 2023 or a 7% decrease. Cost of sales includes depreciation; cost of medicines, medical supplies and laboratory reagents; professional fees, salaries and wages and utilities expense.

The Company’s operating expenses pertain mainly to salaries and wages of administrative employees, repairs and maintenance, allocated depreciation expense, supplies and consumable, and bad debt expense which represent 68% of the Company’s total operating expenses. The total operating expenses increased by 36% or ₱40.9 million in 2024.

In 2024, the Company has generated net income of ₱27.9 million.

Financial Position (2024)

The following table shows the financial position of the Company as at December 31, 2024 and 2023:

	December 31, 2024	% to Total Assets	December 31, 2023	% to Total Assets	% Change
Current assets	178,383,714	21%	193,914,894	22%	-8%
Noncurrent assets	684,559,217	79%	704,192,114	78%	-3%
Total assets	862,942,931	100%	898,107,008	100%	-4%
Current liabilities	246,390,899	29%	251,779,826	28%	-2%
Noncurrent liabilities	53,197,877	6%	141,134,654	16%	-62%
Total Liabilities	299,588,776	35%	392,914,480	44%	-24%
Total Equity	563,354,155	65%	505,192,528	56%	12%
Total liabilities and equity	862,942,931	100%	898,107,008	100%	-4%

Balance Sheet Items - 2024 compared to 2023

Total current assets decreased by 8% or ₱15.5 million in 2024 as compared to 2023. The decrease in current assets is due to decrease in other current assets amounting to ₱42.2 million. The Company has total assets of ₱862.9 million as of December 31, 2024 of which ₱636.1 million or 74% is comprised of the Company's land, building, medical equipment and other properties and equipment.

The liabilities of the Company is mainly consist of trade payable to suppliers, medical practitioners and related parties, and loans payable to the Land bank of the Philippines totaling ₱179.8 million as of December 31, 2024. Total current liabilities have decreased by 24% or ₱93.3 million in 2024 as compared in 2023 due to the principal payment of the bank loans.

Material Variances Affecting the Statements of Financial Position

Statement of financial position accounts as of December 31, 2024 with variances of plus or minus 5 percent against December 31, 2023 balance are discussed, as follows:

Current assets

1. Cash - The increase in cash is due to increase in cash generated from operating activities. The Company has an increase of ₱31.6 million. This was offset by the increase in loan payments. Total payments amounted to ₱122.0 million in 2024 and ₱114.8 million in 2023.
2. Trade Receivable – The increase in trade receivable of 8% is due to the increase in receivable from HMO, Corporate and GLs. In 2024, receivable from HMO, Corporate and GLs increased from ₱20.3 million to ₱37.6 million. This is due to the increased number of patients availing of financial assistance from government agencies.
3. Prepayments and other current assets – The decrease is due to the reclassification of Input VAT to other accounts.

Noncurrent assets

1. Advances to suppliers – The decrease on the account can be attributed to the delivery of goods and/or services.
2. Property and equipment – The decrease is mainly due to the depreciation of the Company's property and equipment totaling to ₱72.4 million.
3. Intangible assets – Increase in intangible asset is due to additions made during the year totaling to ₱3.7 million.

Current and Noncurrent Liabilities

1. Notes payable – In 2024, the Company has paid a total of ₱122.0 million to its long-term notes payable which caused the decrease in total current and noncurrent notes payable.
2. Advances from shareholders – The increase is due to receipts made throughout the year. Total payments for the year was ₱25.6 million.

Key Performance Indicators

The Company's management intends to analyze future results of operations through the following key performance indicators, among other measures:

	Mar. 31, 2026	Dec. 31, 2025	Dec. 31, 2024
CURRENT RATIO = Current assets / Current liabilities	1.01	0.96	0.72
Remarks: The current ratio measures a company's ability to pay short-term obligations or those due within one year. It tells investors and analysts how a company can maximize the current assets on its balance sheet to satisfy its current debt and other payables. Current ratio in 2026 and 2025 increased as net result of the increase in cash and trade receivables.			
DEBT TO EQUITY RATIO = Debt / Equity	0.46	0.54	0.53
Remarks: Debt to equity ratio shows the proportions of equity and debt a company is using to finance its assets and it signals the extent to which shareholder's equity can fulfill obligations to creditors. Debt to equity in 2026 decreased as a net effect of the loan repayments during the year and increase in the retained earnings account of the Company.			
DEBT TO TOTAL ASSET RATIO = Debt / Asset	0.31	0.35	0.35
Remarks: Debt to total asset ratio is an indicator of a company's financial leverage. It is the percentage of a company's total assets that were financed by creditors. Debt to total asset ratio in 2026 decreased as result of principal payments during the year totaling to P34 million which was partially offset by the availment of additional short term loan amounting to P25.0 million. Debt to total asset in 2025 remains the same due to the net effect of decrease in bank loans due to repayment and increase in equity due to profit for the period.			
ASSET TO EQUITY RATIO = Assets / Equity	1.46	1.54	1.53
Remarks: Asset to equity ratio shows the relationship of the total assets of the Company to the portion owned by shareholders. This ratio is an indicator of the company's leverage (debt) used to finance the firm. No significant change in 2025. However, asset to equity ratio in 2026 decreased due to the increase in retained earnings, and increase in share capital and share premium together with the decrease in total assets due to depreciation of property and equipment.			
PROFIT MARGIN = Net Income (Loss) / Net Revenue	0.01	0.04	0.05
Remarks: Profit margin is a measure of the Company's income (loss) relative to its revenue. It represents what percentage of revenue has turned into income or loss. Profit margin in 2026 lower due to the Company's decrease in gross profit for the three-month ended March 31, 2026.			

There were no material events that would trigger direct or indirect contingent financial obligation that would materially affect the company's operation, including any default or acceleration of obligation.

The Company did not enter into any material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships with unconsolidated entities or other persons during the period.

There were no any known trends or any known demands, commitments, events or uncertainties that would result in or that were reasonably likely to result in the Company's liquidity increase or decreasing in any material way.

The Company continues to spend for regular capital expenditures during the quarter as disclosed in Note 10 of the unaudited interim financial statements.

There were no known trends, events or uncertainties that have had or that are reasonably expected to have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations.

There were no significant elements of income or loss that did not arise from the Company's continuing operations.

There were no seasonal aspects that had any material effect on the financial condition or results of operations of the Company.

There were no material events subsequent to the end of the interim period that have not been reflected in the financial adjustments of the interim period.

The Company is not a party to any lawsuit or claims arising from the ordinary course of business

E. Certain Relationships and Related Transactions

- 1) During the last two (2) years, no director of the Company has received or become entitled to receive any benefit by reason of any contract with the Company, a related corporation, a firm of which the director is a member or a company of which a director has a substantial financial interest.

There are no transactions in the last two (2) years or proposed transactions to which the Company was or is to be a party, in which any of the following persons had or is to have a direct or indirect material interest:

- i. Any director or executive officer of the Corporation;
- ii. Any nominee for election as a director;
- iii. Any security holders;
- iv. Any member of the immediate family of the preceding persons.

The Company's related parties include its affiliates and shareholders, the Company's key management personnel and others as described below.

A summary of the transactions and account balances with related parties follows:

The Company, in the normal course of business, transacts business with individuals which are considered related parties. The following were carried out with related parties as at March 31, 2026 and December 31, 2025:

Category	Advances from shareholders 2025	Amount of Transactions 2026	Advances from shareholders 2026	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	47,558,354	2,454,165	50,012,519	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	47,558,354	2,454,165	50,012,519		

Category	Advances from shareholders 2024	Amount of Transactions 2025	Advances from shareholders 2025	Terms	Conditions
Advances from shareholders					
Non-interest-Bearing	27,945,354	3,910,000	31,855,354	Non-interest-bearing, to be paid in cash (a)	Unsecured, unguaranteed, not impaired
Interest Bearing	—	—	—	Interest-bearing, to be paid in cash (b)	Unsecured, unguaranteed, not impaired
	27,945,354	3,910,000	31,855,354		

(a) Non-interest-bearing Advances from shareholders

In the special meeting of the Board held last May 7, 2017, the directors and shareholders were mandated and empowered to contribute resources and make cash advances to the Company for the development of its medical structures and appurtenances. In view of this, the shareholders advanced the monies in support of the Company's building construction requirements. These advances are non-interest bearing and to be paid subject to availability of funds and/or the Board may decide to convert said advances to equity in the distant future. The Company, however, also reserves the right to defer settlement and prioritize completion of the hospital building.

(b) Interest-bearing Advances from shareholders

On June 3, 2019, the Company acquired an unsecured interest-bearing advance from the shareholders at 12% per annum which was primarily used by the Company to support the working capital requirement during the start of its operation. The Company, however, reserves the right to defer settlement in favor of prioritizing payments relative to hospital construction. Total finance costs on these loans amounted to nil, ₱896,230 and ₱1,402,619 in 2024, 2023 and 2022, respectively.

(c) There is no transaction with promoters for the past 5 years.

Family Relationships

Among the directors and officers of Allied Care Experts (ACE) Dumaguete Doctors, Inc., the assistant corporate treasurer, Michael Edward Enriquez, is the son of Dr. Amado Manuel Enriquez, Jr. a member of the Board of Directors.

F. Management and Certain Security Holders

Directors, Executive Officers

There are fifteen (15) members of the Board, three (3) of whom are independent directors who hold office for one (1) year. The Corporation relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Corporation's goals.

There are no family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.

As of April 30, 2026, none of the nominees for election as director, executive officer, underwriter or control person of the registrant has been involved in the following: (1) Bankruptcy; (2) Conviction by final judgment; (3) Being subject to any Order, Judgment or Decree; and (4) Violation of Securities or Commodities Law.

G. Corporate Governance

The Company adheres to the principles of good governance as provided in its Manual on Corporate Governance (MCG). In the performance of their respective responsibilities, the directors, officers and employees are guided by the mission and vision of the Company and the good corporate practices provided under the Company's Manual on Corporate Governance.

The Board has created different committees: Nomination and Election Committee, Audit Committees, Remuneration/Compensation Committee, Committee on Corporate Governance and Committee on Inspection and Validity of Proxies, all composed of qualified members and who undertake their functions as mandated. There were no major deviations from the adopted Manual on Corporate Governance.

The directors and officers attended the following corporate governance seminar on October 9, 2025:

1. Corporate Governance Best Practices of Effective Boards
 - Center for Global Best Practices

The Independent directors have submitted their Certificates of Qualification as required by the SEC vis-à-vis Section 38 of the Securities Regulation Code. The Corporation has filed its Manual on Corporate Governance on June 30, 2023.

The independent directors have submitted their Certificate of Qualification as required by the SEC vis-à-vis Section 38 of the Securities Regulation Code.

ANNEX “C”

**TOP 20 STOCKHOLDERS
As of March 31, 2026**

	NAME	NATIONALITY	TYPE	NUMBER OF SHARES	% OF OWNERSHIP
1	Amado Manuel C. Enriquez Jr.	Filipino	Common	12,450	7.40%
			Founder	50	
			Total	12,500	
2	Marietta T. Samoy	Filipino	Common	7,470	4.44%
			Founder	30	
			Total	7,500	
3	Geanie A. Cerna-Lopez	Filipino	Common	4,330	2.57%
			Founder	10	
			Total	4,340	
4	Roy Diamond M. Arco	Filipino	Common	3,320	1.97%
			Founder	10	
			Total	3,330	
5	Daphne Lyn R. Rana	Filipino	Common	3,120	1.85%
			Founder	10	
			Total	3,130	
6	Brenda V. Diputado	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
7	Ronald I. Ramiro	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
8	Esmeralda V. De La Rosa	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
9	Michael Edward R. Enriquez	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
10	Generoso M. Orillaza	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
11	Aejeleth B. Eyas	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
12	Aideline E. Sison	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
13	Idelle Marie A. Yurong	Filipino	Common	2,490	1.48%

	NAME	NATIONALITY	TYPE	NUMBER OF SHARES	% OF OWNERSHIP
			Founder	10	
			Total	2,500	
14	Angelo L. Alcala	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
15	Angelo Michael A. Singco	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
16	Felicesimo D. De Castro	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
17	Felix P. Nolasco	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
18	Lynn L. Olegario	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
19	Maria Carmelita N. Vera Cruz	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	
20	Brian Joseph M. Calinawagan	Filipino	Common	2,490	1.48%
			Founder	10	
			Total	2,500	

ANNEX “D”

**LIST OF THE DIRECTORS, OFFICERS AND STOCKHOLDERS WHO ATTENDED THE
Y2025 ANNUAL STOCKHOLDERS’ MEETING**

1. Dr. Aejeleth B. Eyas
2. Dr. Aideline E. Sison
3. Dr. Amado Manuel C. Enriquez Jr.
4. Dr. Angelo L. Alcala
5. Dr. Angelo Michael A. Singco
6. Dr. Bernie A. Orhel
7. Dr. Brenda V. Diputado
8. Dr. Brian Joseph M. Calinawagan
9. Dr. Carmelo R. Domingo Jr.
10. Dr. Carlos M. De La Rosa
11. Dr. Concepcion P. Rosario
12. Dr. Corazon D. Uy
13. Dr. Daphne Lyn R. Rana
14. Dr. Daryl M. Apla-on
15. Dr. Esmeralda V. De La Rosa
16. Dr. Eulena P. Nolasco
17. Dr. Evangeline Y. Zozobrado
18. Dr. Felicisimo D. De Castro
19. Dr. Felix P. Nolasco
20. Dr. Franciene P. Vasquez
21. Dr. Geanie A. Cerna-Lopez
22. Dr. Glenda N. Nuico
23. Dr. Idelle Marie A. Yurong
24. Dr. Jane R. Ramiro
25. Dr. Jennifer P. Emperado
26. Dr. Jonathan C. Amante
27. Dr. Junabeth C. Credo
28. Dr. Karen Mae A. Sayson
29. Dr. Lynn L. Olegario
30. Dr. Maita C. Cruz
31. Dr. Maria Carmelita N. Vera Cruz
32. Dr. Maria Rhodora G. De Leon
33. Dr. Marietta T. Samoy
34. Dr. Marilou R. Enriquez
35. Dr. Marilyn R. Enriquez
36. Dr. Marissa A. Orillaza
37. Dr. Mark Joseph C. Lopez
38. Dr. Michael Edward R. Enriquez
39. Dr. Miguel R. Enriquez
40. Dr. Nailani Z. Tan
41. Dr. Nestor Jogie C. Arroyo
42. Dr. Pal K. Amante
43. Dr. Raponzel Josephine A. Fontelo
44. Dr. Revey S. Nuico
45. Dr. Robert H. Tan
46. Dr. Roberto M. De Leon
47. Dr. Rolando E. Regalado
48. Dr. Ronald I. Ramiro
49. Dr. Roy Diamond M. Arco
50. Dr. Silahis O. Rosario
51. Dr. Ver Emerald M. Arco
52. Engr. Generoso M. Orillaza
53. Ernst Caesar R. Rana
54. Felino A. Cerna
55. Wendyl V. Barluado
56. Suzanne Antoniette L. Bascara
57. Mary Ann Claire A. Mann
58. Jorielle Deigh D. Arao
59. Nora Maria Elena T. Osmeña
60. Lester Floyd D. Zamora
61. Christopher V. Ferraren
62. Marvin S. Kho
63. Philmed P. Salindo
64. Rosalinda A. Mosny
65. Daryle Jason G. Yu
66. Jessie E. Mascardo
67. Janice Marie N. Jordan-Yu
68. Muriel V. Tatoy
69. Ian C. Tonelete
70. Bartolome C. Daño
71. Blaize Marc B. Baldebrin
72. Profetiza S. Lim
73. Fairie C. Tale
74. Gayle Louise O. Villarme
75. Sylvera Benedicta Mary Ann C. Voskamp
76. Emmanuel Surban
77. Izzy Martin R. Maxino
78. Sheena Marie D. Daño
79. Camila D. Villanueva
80. Recardo T. Cordova
81. Ian Ray H. Lopez
82. Angeles Lezel C. Basañes
83. Jose F. Dino Jr.
84. Socorrito B. Alcantara
85. Danielle Angelique N. Cabahug
86. Sanda R. Fuentes
87. Sande R. Fuentes
88. Jacky Vincent V. Omandam
89. Windie A. Aba
90. Christine Mae A. Delgado
91. Robert Anthony L. Edjec
92. Lev L. Lopez
93. Nariz Suzy E. Ong
94. Christine D. Daño
95. Edrian Jay P. Tupas
96. Blyth L. Kitane
97. Denver A. Pareja
98. Joel E. Folio

99. Roxanne C. Despojo
100. Maricris Joy T. Regencia
101. Arcile P. Orizonte
102. Aileen Nieves B. De Mesa
103. Jore G. Amistoso
104. Rene T. Opada
105. Marlon P. Baldado
106. Faith C. Amistoso
107. Araceli P. Tumacole
108. Grace Therese A. Logronio
109. Mayaline D. Encabo
110. Karen M. Caminos
111. Mae Anne S. Aum
112. Dizire S. Patun-Og
113. Julia K. Sale
114. Apollo Anthony D. Ang
115. Lucille S. Martinez
116. Riza E. Dy
117. Absalita C. Teves
118. Felix Taguiam
119. Aaron R. Diao
120. Prudencio P. Abique
121. Susano D. Ruperto IV
122. Ava Psyche A. Opada
123. Daphne Christine C. Malicay
124. Michael Jeffrey T. Pacurza
125. Wilgee Eila S. Abbot
126. Liznil Gabutero Alonzo
127. Pacita A. Alonzo
128. Noemi Q. Sun
129. Cherry A. Ravelo
130. Gabriel M. Sanson
131. Neil Vic A. Divinagracia
132. Rolito R. Sondon
133. Marecor P. Gabuya
134. Miguel Andrey A. Del Villar
135. Aileen Rosette M. Felix
136. Melanie Mae O. Austero
137. Ma. Gracia Mae S. Whitfield
138. Mary Joy M. Candelario
139. Crislyn P. Vidal
140. Geraldine F. Tan
141. Honey Mae R. Grepon
142. Gavin Morey Vivares Tatoy
143. Cristina Rissa L. Enriquez
144. Aldin A. Legaspi
145. Nessa V. Catostos
146. Maria Chona T. Fernandez
147. Christian N. Casamayor
148. Love T. Villareal
149. Renante Oliver M. Lavadia
150. Noel B. Ibero
151. Phyllis M. Sontillanosa
152. Chloe Marie C. Samarita
153. Belinda B. Balor
154. Maeben Xyza Marie C. Ho-Tagimacruz
155. Jennifer Quintos
156. Fritzie Culi-Macias
157. Reniell Rubin Bucita
158. Claudilene A. Tabay
159. Anne E. Melodia
160. Apolinario B. Bautista
161. Myra M. Echon
162. Gerardo Velicaria

ANNEX “E”

ATTENDANCE OF DIRECTORS

	January 9, 2025	February 13, 2025	March 13, 2025	April 10, 2025	May 8, 2025	June 11, 2025	July 3, 2025	July 10, 2025	August 14, 2025	Septemb er 11, 2025	October 9, 2025	Novembe r 6, 2025	Decemb er 11, 2025	% of Attendan ce
Dr. Amado Manuel C. Enriquez Jr. (Chair)	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Geanie Cerna-Lopez (Vice-chair)	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Jonathan Amante	A	A	P	P	A	A	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	33%
Dr. Robert H. Tan (President)	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Marietta Samoy (Vice President)	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Aejeleth Eyas (Secretary)	P	P	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	100%
Dr. Ronald Ramiro (Asst. Secretary)	P	P	P	P	P	P	P	P	P	P	A	P	P	92%
Dr. Roy Diamond Arco (Treasurer)	P	P	A	P	A	A	P	P	P	P	P	A	P	69%
Mr. Carlos De La Rosa	P	A	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	83%
Dr. Corazon Uy	P	P	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	100%
Dr. Roberto De Leon	A	A	P	A	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	50%
Dr. Glenda Nuico	P	P	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	100%
Dr. Rolando Regalado (ID)	A	A	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	67%
Engr. Generoso Orillaza (ID)	P	P	P	P	P	P	P	P	P	P	P	P	P	100%
Dr. Evangeline Zozobrado (ID)	P	P	P	P	P	P	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	NLAD	100%
Dr. Michael Edward Enriquez (Asst. Treasurer)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	100%
Dr. Brenda Diputado (Secretary)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	A	A	P	71%
Dr. Idelle Marie A. Yurong (Director)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	100%
Dr. Revey Nuico (Director)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	100%
Dr. Franciene Vasquez (Director)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	A	P	P	P	A	P	P	71%
Dr. Esmeralda De La Rosa (Director)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	P	P	P	100%
Dr. Concepcion Rosario (ID)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	A	P	P	P	P	P	86%
Dr. Eulenia Nolasco (ID)	NYAD	NYAD	NYAD	NYAD	NYAD	NYAD	P	P	P	P	A	A	P	71%

Legend: P – Present ; A – Absent; NYAD – Not Yet A Director; NLAD – No Longer A Director

